[Skip to Navigation]

July 2021 - July 1883

Decade

Year

Issue

August 4, 2020, Vol 324, No. 5, Pages 419-524

In This Issue of JAMA

Audio Highlights

Abstract Full Text
free access online only has audio
JAMA. 2020;324(5):e200031. doi:10.1001/jama.2020.0031
Original Investigation

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Abstract Full Text
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):460-470. doi:10.1001/jama.2020.10044

This randomized trial compares the effects of convalescent plasma therapy with standard care vs standard care alone on time to clinical improvement among patients with severe or life-threatening COVID-19 disease in China.

Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial

Abstract Full Text
free access has active quiz
JAMA. 2020;324(5):471-480. doi:10.1001/jama.2020.10224

This randomized clinical trial compares the effects of vitamin D₃ supplementation vs placebo on depression risk and mood scores in men and women aged 50 years or older.

Association of Diagnosis Coding With Differences in Risk-Adjusted Short-term Mortality Between Critical Access and Non–Critical Access Hospitals

Abstract Full Text
free access
JAMA. 2020;324(5):481-487. doi:10.1001/jama.2020.9935

This study uses Medicare data to estimate mortality differences for common medical conditions (pneumonia, heart failure, chronic obstructive pulmonary disease, urinary tract infection, others) at US critical access vs non–critical access hospitals between 2007 and 2017 with vs without adjustment for discharge diagnosis counts to assess the extent to which coding practices rather than illness severity might account for observed mortality differences.

Research Letter

Mortality, Admissions, and Patient Census at SNFs in 3 US Cities During the COVID-19 Pandemic

Abstract Full Text
free access has active quiz
JAMA. 2020;324(5):507-509. doi:10.1001/jama.2020.11642

This study uses Medicare’s Nursing Home Compare and a university long-term care database to compare census, admissions, discharges, and mortality at skilled nursing facilities (SNFs) in 3 metropolitan areas during March-May 2020 vs March-May 2019.

Excess Deaths From COVID-19 and Other Causes, March-April 2020

Abstract Full Text
free access has multimedia has audio
JAMA. 2020;324(5):510-513. doi:10.1001/jama.2020.11787

This study uses data from the National Center for Health Statistics to estimate excess deaths (ie, the difference between observed and expected deaths) in the US and the District of Columbia in the early weeks of the COVID-19 pandemic.

Prevalence, Characteristics, and Costs of Urgent Care Center Membership Programs

Abstract Full Text
free access
JAMA. 2020;324(5):513-514. doi:10.1001/jama.2020.7317

This study uses simulated patient phone calls to a random selection of US urgent care clinics (UCCs) to describe the proportion that offer membership programs with access to discounted visits for recurring fees and the characteristics (affiliations, accreditations, population income) and fees and charges of those that do.

Viewpoint

Academic Medicine and Black Lives Matter: Time for Deep Listening

Abstract Full Text
has multimedia has audio
JAMA. 2020;324(5):435-436. doi:10.1001/jama.2020.12532

In the context of the Black Lives Matter movement, this Viewpoint considers the demand that academic medicine address its own structural racism, and concludes on the basis of its history, culture, role, and influence that the institution can, should, and must make racial justice a part of its work and mission.

Developing a SARS-CoV-2 Vaccine at Warp Speed

Abstract Full Text
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):437-438. doi:10.1001/jama.2020.12190

This Viewpoint discusses the mechanisms of the 5 leading COVID-19 vaccine candidates—2 messenger RNA vaccines, 1 recombinant VSV vector product, and 2 replication-defective adenovirus vector approaches—and emphasizes the need to demonstrate safety as well as efficacy to facilitate broad uptake by the public.

The Development of COVID-19 Vaccines: Safeguards Needed

Abstract Full Text
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):439-440. doi:10.1001/jama.2020.12461

This Viewpoint lists 4 safeguards policy makers should consider before release of a COVID-19 vaccine, including ensuring effectiveness through clinical trials, providing evidence of safety, requiring informed consent before vaccination, and establishing comprehensive adverse effects monitoring systems.

Airborne Transmission of SARS-CoV-2: Theoretical Considerations and Available Evidence

Abstract Full Text
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):441-442. doi:10.1001/jama.2020.12458

This Viewpoint discusses physical and epidemiological evidence supporting droplet vs aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and concludes on balance that aerosol transmission seems unlikely to be the dominant mode of coronavirus disease 2019 (COVID-19) spread.

Communicating Science in the Time of a Pandemic

Abstract Full Text
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):443-444. doi:10.1001/jama.2020.12535

This Viewpoint uses the example of rapid changes to public reporting on the efficacy of hydroxychloroquine and remdesivir for COVID-19 to illustrate how misinformation damages the public’s trust in science and medicine, and urges accuracy and circumspection in news reports of developments in the pandemic.

Challenges Estimating Total Lives Lost in COVID-19 Decisions: Consideration of Mortality Related to Unemployment, Social Isolation, and Depression

Abstract Full Text
free access has active quiz
JAMA. 2020;324(5):445-446. doi:10.1001/jama.2020.12187

This Viewpoint discusses how COVID-19–related policy decisions lead to trade-offs between medical, economic, social, and psychological outcomes, and emphasizes the need to account for deaths associated with unemployment and depression when estimating excess mortality.

Behavioral Health Parity Efforts in the US

Abstract Full Text
JAMA. 2020;324(5):447-448. doi:10.1001/jama.2020.3505

This Viewpoint discusses halting progress in legislative and policy attempts to make access to high-quality mental health and substance use disorders service equal to that for medical-surgical services and prospects for further regulation of insurance to achieve the goal.

Assessing Quantitative Comparisons of Health and Social Care Between Countries

Abstract Full Text
has audio
JAMA. 2020;324(5):449-450. doi:10.1001/jama.2020.3813

This Viewpoint discusses differences that complicate cross-country comparisons of health and social services and proposes a framework for assessing the appropriateness of those comparisons to help researchers improve their investigations and help readers critically appraise them.

A Piece of My Mind

Eradicating Racial Injustice in Medicine—If Not Now, When?

Abstract Full Text
JAMA. 2020;324(5):451-452. doi:10.1001/jama.2020.12432

In this narrative medicine essay, a urology fellow offers 5 actions the medical community should take to eliminate racial injustice and health disparities in the United States.

Editorial

Editorial Evaluation and Peer Review During a Pandemic: How Journals Maintain Standards

Abstract Full Text
free access has active quiz
JAMA. 2020;324(5):453-454. doi:10.1001/jama.2020.11764

A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals

Abstract Full Text
free access has active quiz
JAMA. 2020;324(5):455-457. doi:10.1001/jama.2020.10218

Mortality and Morbidity: The Measure of a Pandemic

Abstract Full Text
free access has audio
JAMA. 2020;324(5):458-459. doi:10.1001/jama.2020.11761
Review

Heart Failure With Reduced Ejection Fraction: A Review

Abstract Full Text
has active quiz has audio
JAMA. 2020;324(5):488-504. doi:10.1001/jama.2020.10262

This narrative review summarizes the epidemiology, pathophysiology, diagnosis, management, and prognosis of heart failure with reduced ejection fraction.

From The Medical Letter on Drugs and Therapeutics

Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy

Abstract Full Text
JAMA. 2020;324(5):505. doi:10.1001/jama.2020.0753

This Medical Letter review describes how tafamidis prevents transthyretin protein complexes from disocciating into amyloid fibrils, and its recent approval in 2 different formulations (Vyndaqel and Vyndamax) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Medical News & Perspectives

Taking a Closer Look at COVID-19, Health Inequities, and Racism

Abstract Full Text
free access has active quiz has multimedia has audio
JAMA. 2020;324(5):427-429. doi:10.1001/jama.2020.11672

This Medical News article is an interview with Chicago public health legend and retired physician Linda Rae Murray, MD, MPH, an adjunct assistant professor at the University of Illinois at Chicago School of Public Health and a past president of the American Public Health Association.

News From the Food and Drug Administration

Breast Cancer Drug Can Be Given at Home or in the Clinic

Abstract Full Text
JAMA. 2020;324(5):433. doi:10.1001/jama.2020.13100

First-in-Class HIV Drug Is Approved

Abstract Full Text
JAMA. 2020;324(5):433. doi:10.1001/jama.2020.13103

Immunotherapy Is Now First-line Therapy for Some Colorectal Cancers

Abstract Full Text
JAMA. 2020;324(5):433. doi:10.1001/jama.2020.13299
The JAMA Forum

COVID-19 and Massive Job Losses Will Test the US Health Insurance Safety Net

Abstract Full Text
free access
JAMA. 2020;324(5):431-432. doi:10.1001/jama.2020.12248
Bench to Bedside

Virus Surveillance and Diagnosis With a CRISPR-Based Platform

Abstract Full Text
JAMA. 2020;324(5):430. doi:10.1001/jama.2020.12669
Poetry and Medicine

Remains

Abstract Full Text
JAMA. 2020;324(5):520. doi:10.1001/jama.2020.5364
JAMA Revisited

The Future of the Physician

Abstract Full Text
JAMA. 2020;324(5):521. doi:10.1001/jama.2019.13554
JAMA Patient Page

Convalescent Plasma and COVID-19

Abstract Full Text
free access has active quiz
JAMA. 2020;324(5):524. doi:10.1001/jama.2020.10699

This JAMA Patient Page describes the possible benefits of convalescent plasma transfusion in the treatment of COVID-19 as well as plasma donation eligibility criteria.

Comment & Response

Intravenous Interferon β-1a for Severe ARDS

Abstract Full Text
JAMA. 2020;324(5):515. doi:10.1001/jama.2020.7980

Intravenous Interferon β-1a for Severe ARDS—Reply

Abstract Full Text
JAMA. 2020;324(5):515-516. doi:10.1001/jama.2020.7992

Research and Development Costs of New Drugs

Abstract Full Text
JAMA. 2020;324(5):516. doi:10.1001/jama.2020.8645

Research and Development Costs of New Drugs

Abstract Full Text
JAMA. 2020;324(5):516-517. doi:10.1001/jama.2020.8642

Research and Development Costs of New Drugs

Abstract Full Text
JAMA. 2020;324(5):517. doi:10.1001/jama.2020.8648

Research and Development Costs of New Drugs—Reply

Abstract Full Text
JAMA. 2020;324(5):518. doi:10.1001/jama.2020.8651

Errors in Trial of Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

Abstract Full Text
JAMA. 2020;324(5):518-519. doi:10.1001/jama.2020.12607
Correction

Correction to Data in Trial of Convalescent Plasma Treatment for COVID-19

Abstract Full Text
free access
JAMA. 2020;324(5):519. doi:10.1001/jama.2020.13216
JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2020;324(5):419-420. doi:10.1001/jama.2019.13547
×